Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab versus omalizumab and placebo in chronic spontaneous urticaria
NL-OMON52375Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ligelizumab in chronic idiopathic urticaria (CIU) (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline in UAS7 at Week 12. Started Apr 2019; status: recruiting.
02
Drugs
ligelizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NL-OMON52375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52375.